WO2001004148A3 - Donor strand complemented pilin and adhesin broad-based vaccines - Google Patents

Donor strand complemented pilin and adhesin broad-based vaccines Download PDF

Info

Publication number
WO2001004148A3
WO2001004148A3 PCT/US2000/019066 US0019066W WO0104148A3 WO 2001004148 A3 WO2001004148 A3 WO 2001004148A3 US 0019066 W US0019066 W US 0019066W WO 0104148 A3 WO0104148 A3 WO 0104148A3
Authority
WO
WIPO (PCT)
Prior art keywords
pilin
polypeptides
pilus
disclosed
complexes
Prior art date
Application number
PCT/US2000/019066
Other languages
French (fr)
Other versions
WO2001004148A2 (en
WO2001004148A9 (en
Inventor
Scott J Hultgren
Jerome S Pinkner
Frederic Sauer
Michelle Barnhart
Gabriel Waksman
Stefan Knight
Original Assignee
Medimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Inc filed Critical Medimmune Inc
Priority to CA002373534A priority Critical patent/CA2373534A1/en
Priority to JP2001509757A priority patent/JP2003504083A/en
Priority to EP00947305A priority patent/EP1194561A2/en
Priority to AU60940/00A priority patent/AU6094000A/en
Publication of WO2001004148A2 publication Critical patent/WO2001004148A2/en
Publication of WO2001004148A3 publication Critical patent/WO2001004148A3/en
Publication of WO2001004148A9 publication Critical patent/WO2001004148A9/en
Priority to HK02106980.7A priority patent/HK1045713A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Modified polypeptides containing a pilus-protein sequence and a donor complementary sequence are disclosed, as well as complexes formed of a modified polypeptide and a pilin, or pilus-protein. Also disclosed are methods of using these novel polypeptides as a means of preventing and/or treating bacterial induced diseases, especially those caused by enterobacteria such as Escherichia coli. Methods of employing these modified pilus-derived polypeptides and complexes as vaccines and for generating antibodies for further study as well as for clinical purposes are also disclosed herein. In addition, processes for large scale production of antibacterial vaccines containing said polypeptides and complexes are also described.
PCT/US2000/019066 1999-07-13 2000-07-13 Donor strand complemented pilin and adhesin broad-based vaccines WO2001004148A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002373534A CA2373534A1 (en) 1999-07-13 2000-07-13 Donor strand complemented pilin and adhesin broad-based vaccines
JP2001509757A JP2003504083A (en) 1999-07-13 2000-07-13 Donor-chain complementary pilin-adhesin broad-based vaccine
EP00947305A EP1194561A2 (en) 1999-07-13 2000-07-13 Donor strand complemented pilin and adhesin broad-based vaccines
AU60940/00A AU6094000A (en) 1999-07-13 2000-07-13 Donor strand complemented pilin and adhesin broad-based vaccines
HK02106980.7A HK1045713A1 (en) 1999-07-13 2002-09-25 Donor strand complemented pilin and adhesin broad-based vaccines

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US14358299P 1999-07-13 1999-07-13
US60/143,582 1999-07-13
US14435999P 1999-07-16 1999-07-16
US60/144,359 1999-07-16
US18444200P 2000-02-23 2000-02-23
US60/184,442 2000-02-23

Publications (3)

Publication Number Publication Date
WO2001004148A2 WO2001004148A2 (en) 2001-01-18
WO2001004148A3 true WO2001004148A3 (en) 2001-06-28
WO2001004148A9 WO2001004148A9 (en) 2001-07-26

Family

ID=27385951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/019066 WO2001004148A2 (en) 1999-07-13 2000-07-13 Donor strand complemented pilin and adhesin broad-based vaccines

Country Status (6)

Country Link
EP (1) EP1194561A2 (en)
JP (1) JP2003504083A (en)
AU (1) AU6094000A (en)
CA (1) CA2373534A1 (en)
HK (1) HK1045713A1 (en)
WO (1) WO2001004148A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004502447A (en) * 2000-07-07 2004-01-29 メディミューン，インコーポレイテッド FimH adhesin proteins and methods of use
CA2420234A1 (en) * 2000-08-18 2002-02-28 Medimmune, Inc. Method of administering fimh protein as a vaccine for urinary tract infections
WO2002059156A2 (en) 2000-12-22 2002-08-01 Medimmune, Inc. Therapeutic compounds structurally-linked to bacterial polypeptides
US9079945B2 (en) 2005-01-11 2015-07-14 Naval Medical Research Center Adhesin as immunogen against enterotoxigenic Escherichia coli
WO2007117339A2 (en) 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
WO2012028697A1 (en) 2010-09-01 2012-03-08 Eth Zürich, Institute Of Molecular Biology And Biophysics Affinity purification system based on donor strand complementation
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
BR112019025019A2 (en) * 2017-05-31 2020-06-30 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food isolated clostridium perfringens pilus polypeptide, immunogenic polypeptide, vector, vaccine, use of an immunogenic polypeptide, treatment method, antibody, method for detecting infection and method for detecting an immunogenic polypeptide
MX2022005252A (en) * 2019-11-01 2022-06-08 Pfizer Escherichia coli compositions and methods thereof.
CA3202549A1 (en) * 2020-12-02 2022-06-09 Glaxosmithkline Biologicals Sa Novel antigens
WO2023223796A1 (en) * 2022-05-16 2023-11-23 株式会社アデノプリベント Antibody binding to colibactin-producing escherichia coli bacterium

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DODSON, K. W. ET AL.: "Outer-membrane PapC molecular usher discriminately recognizes periplasmic chaperone-pilus subunit complexes", PNAS, vol. 90, April 1993 (1993-04-01), pages 3670 - 3674, XP002155906 *
JONES, C. H. ET AL.: "FimC is a periplasmic PapD-like chaperone that directs assembly of type 1 pili in bacteria", PNAS, vol. 90, September 1993 (1993-09-01), pages 8397 - 8401, XP002155905 *
LANGERMANN, S. ET AL.: "Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.", J. INFECT. DIS., vol. 181, February 2000 (2000-02-01), pages 774 - 778, XP000971593 *
THANKAVEL ET AL: "Localization of a domain in the FimH Adhesin of Escherichia coli Type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection", JOURNAL OF CLINICAL INVESTIGATION,US,NEW YORK, NY, vol. 100, no. 5, September 1997 (1997-09-01), pages 1123 - 1136, XP002109165, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
WO2001004148A2 (en) 2001-01-18
EP1194561A2 (en) 2002-04-10
WO2001004148A9 (en) 2001-07-26
HK1045713A1 (en) 2002-12-06
JP2003504083A (en) 2003-02-04
AU6094000A (en) 2001-01-30
CA2373534A1 (en) 2001-01-18

Similar Documents

Publication Publication Date Title
WO2001004148A3 (en) Donor strand complemented pilin and adhesin broad-based vaccines
PT624377E (en) CONJUGATES OF ANTICIPATED PHARMACISTS CLOSED BY LYSOSOMIC ENZYMES
BG101384A (en) New pesticide proteins and strains
EP1731166A3 (en) Streptococcus pneumoniae proteins and vaccines
CA2381770A1 (en) Human ctla-4 antibodies and their uses
DE69434784D1 (en) BACTERIAL EXTRACTION PROTEINS AND CORPORATE AZELLULAR VACCINES
ZA965752B (en) Triphenylethylenes, process for their production, pharmaceutical preparations that contain these triphenylethylenes as well as their use for the production of pharmaceutical agents.
WO2001010894A3 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
DE59912185D1 (en) USE OF HSP70 PROTEIN
WO2001016327A3 (en) Method for producing a channel-forming protein
NZ504669A (en) Virulence-associated nucleic acid sequences and uses in identification of anti-virulence agents
AU2001258373A1 (en) Method for identifying helicobacter antigens
WO1997023624A3 (en) Polynucleotides and polypeptides in pathogenic mycobacteria and their use as diagnostics, vaccines and targets for chemotherapy
CA2236699A1 (en) Immunity against actinobacillus pleuropneumoniae's rtx toxins apx
EA200100700A1 (en) GENES AND PROTEINS AND THEIR APPLICATION
WO2002012468A3 (en) 2,5-dkg permeases
WO2003004517A3 (en) Peyers's patch and/or m-celle targeting ligands
WO2000078956A8 (en) Novel pyrrhocoricin-derived peptides, and methods of use thereof
WO2001064876A3 (en) Human schizophrenia gene
WO2001096873A3 (en) Method for identifying apoptosis-modified proteins
EP0780472A3 (en) Stress proteins
MY136784A (en) Global regulators of bacterial pathogenic genes as targets for engineering disease resistance
WO2002018611A3 (en) Method for the improved production and isolation of trans-dihydroxycyclohexadiene carboxylic acids and/or derivatives thereof and a genetically modified organism suitable for the above
WO2003084965A8 (en) N-(3-rifamycinyl)-carbamates, method of preparing them and their use for treating and preventing tuberculosis
WO2000052147A3 (en) Bacterial prolyl peptidases and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/12-12/12, DRAWINGS, REPLACED BY NEW PAGES 1/16-16/16; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2373534

Country of ref document: CA

Ref country code: CA

Ref document number: 2373534

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000947305

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 60940/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000947305

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000947305

Country of ref document: EP